Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with wilms' tumor: A report from the national wilms' tumor study group

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 237-245

  Green, Daniel M ^a   Breslow, Norman E ^a   Beckwith, J Bruce ^a   Finklestein, Jerry Z ^a   Grundy, Paul E ^a   Thomas, Patrick R ^a   Kim, Tae ^a   Shochat, Stephen J ^a   Haase, Gerald M ^a   Ritchey, Michael L ^a   Kelalis, Panayotis P ^a   D'Angio, Giulio J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; VINCRISTINE SULFATE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLEAR CELL SARCOMA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEALTH CARE COST; HUMAN; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; RANDOMIZED CONTROLLED TRIAL;

EID: 0031983155     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.237     Document Type: Article

References (37)

1. D'Angio GJ, Evans AE, Breslow N, et al: The treatment of Wilms' tumor. Results of the National Wilms' Tumor Study. Cancer 38:633-646, 1976
2. D'Angio GJ, Evans A, Breslow N, et al: The treatment of Wilms' tumor: Results of the Second National Wilms' Tumor Study. Cancer 47:2302-2311, 1981
3. D'Angio GJ, Breslow N, Beckwith JB, et al: Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 64:349-360, 1989
4. Response of Ridgway Osteosarcoma (ROS) at Different Stages to a Variety of Drugs Given According to Different Schedules. Birmingham, AL, Southern Research Institute, 1977, pp 32-33, 49
5. Goldin A, Johnson RK: Experimental tumor activity of Adriamycin (NSC-123127). Cancer Chemother Rep 6:137-145, 1975
6. Benjamin RS, Hall SW, Burgess MA, et al: A pharmacokinetically based phase I-II study of single-dose actinomycin D(NSC-3053). Cancer Treat Rep 60:289-291, 1976
7. Green DM, Sallan SE, Krishan A: Actinomycin D in childhood acute lymphocytic leukemia. Cancer Treat Rep 62:829-831, 1978
8. Green DM: Evaluation of single-dose vincristine, actinomycin D and cyclophosphamide in childhood solid tumors. Cancer Treat Rep 62:1517-1520, 1978
9. Blatt J, Trigg ME, Pizzo PA, et al: Tolerance to single-dose dactinomycin in combination chemotherapy for solid tumors. Cancer Treat Rep 65:145-147, 1981
10. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin chemotherapy - Efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule. Cancer 33:19-27, 1974
11. O'Bryan RM, Baker LH, Gottlieb JE, et al: Dose response evaluation of Adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
12. Murphy WM, Beckwith JB, Farrow GM: Tumours of the kidney, bladder, and related urinary structures, in Atlas of Tumor Pathology, Third Series, Fascicle 11. Washington, DC, Armed Forces Institute of Pathology, 1994
13. Green DM, Finklestein JZ, Norkool P, et al: Severe hepatic toxicity after treatment with single dose dactinomycin and vincristine. Cancer 62:270-273, 1988
14. Green DM, Norkool P, Breslow N, et al: Severe hepatic toxicity after treatment with vincristine and actinomycin D using single-dose or divided dose schedule. J Clin Oncol 8:1525-1530, 1990
15. Green DM, Breslow NE, Beckwith JB, et al: The treatment of children with clear cell sarcoma of the kidney. A report from the National Wilms Tumor Study Group. J Clin Oncol 12:2132-2137, 1994
16. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 33:457-481, 1958
17. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc (A) 135:185-206, 1972
18. Greenwood M: The Natural Duration of Cancer, in Reports on Public Health and Medical Subjects 33. London, United Kingdom, Her Majesty's Stationery Office, 1926, pp 1-26
19. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-220, 1972
20. Green DM, Beckwith JB, Breslow NE, et al: The treatment of children with stages II-IV anaplastic Wilms' tumor. A report from the National Wilms' Tumor Study Group. J Clin Oncol 12:2126-2131, 1994
21. Goldin A, Johnson RK: Evaluation of actinomycins in experimental systems. Cancer Chemother Rep 58:63-77, 1974
22. Skipper HE: Dose intensity versus total dose of chemotherapy: An experimental basis, in Devita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology 1990. Philadelphia, PA, Lippincott, 1990, pp 43-64
23. Hryniuk WM: The importance of dose intensity in the outcome of chemotherapy, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology 1988. Philadelphia, PA, Lippincott, 1988, pp 121-141
24. Carli M, Pastore G, Perilongo G, et al: Tumor response and toxicity after single-dose versus standard 5-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 6:654-658, 1988
25. de Camargo B, Franco EL, Brazilian Wilms' Tumor Study Group: Single-dose versus fractionated-dose dactinomycin in the treatment of Wilms tumor. Cancer 67;2990-2996, 1991
26. de Camargo B, Franco EL, Brazilian Wilms' Tumor Study Group: A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor. Cancer 73:3081-3086, 1994
27. Staquet M, Dalesio O: Designs for phase II trials, in Buyse ME, Staquet MJ, Sylvester RJ, et al (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1984, pp 261-275
28. Feusner JH, Beckwith JB, D'Angio GJ: Clear cell sarcoma of the kidney: Accuracy of imaging methods for detecting bone metastases. Med Pediatr Oncol 18:225-227, 1990
29. Gururangan S, Wilimas JA, Fletcher BD: Bone metastases in Wilms' tumor - Report of three cases and review of literature. Pediatr Radiol 24:85-87, 1994
30. Bonnin JM, Rubinstein LJ, Palmer NF, et al: The association of embryonal tumors originating in the kidney and in the brain. Cancer 54:2137-2146, 1984
31. Green DM, Breslow NE, Evans I, et al: The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms tumor. A report from the National Wilms' Tumor Study. Am J Pediatr Hematol Oncol 16:207-212, 1994
32. Raine J, Bowman A, Wallendszuz K, et al: Hepatopathythrombocytopenia syndrome - A complication of dactinomycin therapy for Wilms' tumor: A report from the United Kingdom Children's Cancer Study Group. J Clin Oncol 9:268-273, 1991
33. Carli M, Bisoano G, DeKraker J, et al: Clinical and subclinical veno-occlusive disease (VOD) in non-irradiated Wilms' tumor after actinomycin D (ACT-D) and vincristine (VCR) - SIOP 9 study. Med Pediatr Oncol 19:424, 1991 (abstr)
34. de Camargo B: Hepatotoxicity and actinomycin D. Lancet 335:1290, 1990 (letter)
35. Green DM, Finkelstein JZ, Tefft M, et al: Diffuse interstitial pneumonitis after pulmonary irradiation for metastatic Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 63:450-453, 1989
36. Green DM, Breslow NE, Moksness J, et al: Congestive heart failure following initial therapy for Wilms' tumor. A report from the National Wilms Tumor Study. Pediatr Res 35:161A, 1994 (abstr)
37. Wilimas JA, Douglas EC, Lewis S, et al: Reduced therapy for Wilms' tumor: Analysis of treatment results from a single institution. J Clin Oncol 6:1630-1635, 1988